GlassScriptPhysician profile
Kayla Sherman
NPI 1063169480
$3,021.33
in general payments reported to CMS, 2019-2025
25 companies · $1,467 in 2025
The $1,467 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $371 · 2023: $493 · 2024: $690 · 2025: $1,467.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,651.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,650.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $802.29 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $459.81 | 2022-2025 | Caplyta |
| Abbvie INC. | $354.20 | 2022-2025 | |
| Xeris Pharmaceuticals, INC. | $217.71 | 2023-2025 | Gvoke Hypopen |
| Grifols USA, LLC | $211.79 | 2022-2025 | Prolastin-C Liquid |
| Axsome Therapeutics, INC. | $173.35 | 2023-2025 | Auvelity |
| Exact Sciences Corporation | $142.68 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $75.93 | 2023 | |
| Vanda Pharmaceuticals INC. | $74.82 | 2025 | Fanapt |
| Glaxosmithkline, LLC. | $69.85 | 2023-2025 | Trelegy Ellipta |
| Lilly USA, LLC | $68.71 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Pfizer INC. | $47.14 | 2022-2025 | |
| Antares Pharma, INC. | $44.61 | 2024-2025 | Xyosted |
| Corcept Therapeutics | $42.40 | 2025 | Korlym |
| Novo Nordisk INC | $40.38 | 2022-2023 | Ozempic, Rybelsus |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $25.36 | 2024 | Glassia |
| Lundbeck LLC | $23.69 | 2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.52 | 2022 | |
| Novartis Pharmaceuticals Corporation | $19.64 | 2023 | |
| Mylan Specialty L.P. | $19.24 | 2023 | Yupelri |
| Dexcom, INC. | $19.17 | 2024 | Dexcom G6 Transmitter |
| Allergan, INC. | $19.17 | 2022 | |
| Scpharmaceuticals INC. | $17.68 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $17.64 | 2025 | Zoryve |
| Otsuka America Pharmaceutical, INC. | $13.55 | 2023 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kayla Sherman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.